MUMBAI, India, Oct. 12 -- Intellectual Property India has published a patent application (202617103530 A) filed by Clichembio, Inc. on August 27, 2026, for Albumin Nanoplatform For Boron Neutron Capture Therapy And Composition For Boron Neutron Capture Therapy Comprising Same.
Inventors include Lee, Yun Sang; Park, Ji Yong; Yoo, Ran Ji --; Kim, Kyuwan; Niwa, Takashi; and Hosoya, Takamitsu Republic.
The application for the patent was published on October 09, 2026, under issue no. 41/2026.
Abstract: The present invention relates to an albumin nanoplatform for boron neutron capture therapy and a composition for boron neutron capture therapy comprising same. The albumin-based nanoplatform according to the present disclosure can effectively deliver boron to specific tumor tissues by simultaneously conjugating a boron compound containing an excessive amount of boron and a targeting molecule as a carrier for specifically targeting tumor tissues via click chemistry functional groups introduced into the albumin surface. In particular, the nanoplatform enables sufficient delivery of boron molecules to target tumor tissues even at doses less than one- tenth of those required by conventional boron neutron capture therapy (BNCT) drugs, and thus can be applied as a composition for boron neutron capture therapy and as an anticancer therapeutic agent.
Disclaimer: Curated by HT Syndication.
